Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002204427 | SCV002494314 | likely benign | Cystic fibrosis | 2021-02-24 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002204427 | SCV002647696 | pathogenic | Cystic fibrosis | 2017-01-18 | criteria provided, single submitter | clinical testing | The 3T variant is an alteration located in the intron 9 poly-thymidine tract of the CFTR gene. Typically the poly-T tract consists of 5, 7, or 9 thymidine repeats. The efficiency of exon 10 splicing consistently decreases with shorter poly-T tracts, resulting in a lower than normal level of fulllength CFTR protein. The effect of poly-T on exon 10 splicing is also influenced by the adjacent TG tract, usually 11, 12, or 13 TG repeats, with a higher TG number being associated with reduced splicing efficiency resulting in more CFTR mRNA transcripts lacking exon 10 (Sosnay et al. Pediatr Clin North Am 2016;63(4):585-98). The 3T variant was first identified in trans with a pathogenic CFTR mutation in a male with a mild cystic fibrosis phenotype characterized by pulmonary symptoms with recurrent infections, elevated sweat chloride concentrations, and pancreatic sufficiency (Buratti et al. EMBO J 2001;20(7):1774-84). Functional studies involving minigene assays and transfection of different cell lines show that the 3T variant decreases the level of correctly spliced CFTR mRNA, and thus the level of functional CFTR protein (Buratti et al. EMBO J 2001;20(7):1774-84; Disset et al. Hum Mutat 2005;25(1):72-81). |